• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Biomedical and Pharmaceutical Sciences
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 8 (2025)
Volume Volume 7 (2024)
Volume Volume 6 (2023)
Volume Volume 5 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2021)
Volume Volume 3 (2020)
Volume Volume 2 (2019)
Volume Volume 1 (2018)
Zeidan, E., Khalifa, M., Taye, A. (2022). Animal models of pulmonary hypertension; going beyond classical models of induction. Journal of Advanced Biomedical and Pharmaceutical Sciences, 5(4), 151-156. doi: 10.21608/jabps.2022.148245.1160
Esraa Zeidan; Montaser Abdulhakim Khalifa; Ashraf Taye. "Animal models of pulmonary hypertension; going beyond classical models of induction". Journal of Advanced Biomedical and Pharmaceutical Sciences, 5, 4, 2022, 151-156. doi: 10.21608/jabps.2022.148245.1160
Zeidan, E., Khalifa, M., Taye, A. (2022). 'Animal models of pulmonary hypertension; going beyond classical models of induction', Journal of Advanced Biomedical and Pharmaceutical Sciences, 5(4), pp. 151-156. doi: 10.21608/jabps.2022.148245.1160
Zeidan, E., Khalifa, M., Taye, A. Animal models of pulmonary hypertension; going beyond classical models of induction. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2022; 5(4): 151-156. doi: 10.21608/jabps.2022.148245.1160

Animal models of pulmonary hypertension; going beyond classical models of induction

Article 1, Volume 5, Issue 4, October 2022, Page 151-156  XML PDF (554.32 K)
Document Type: Review Articles
DOI: 10.21608/jabps.2022.148245.1160
View on SCiNiTO View on SCiNiTO
Authors
Esraa Zeidan email 1; Montaser Abdulhakim Khalifa2; Ashraf Taye3
1Department of pharmacology and toxicology, faculty of pharmacy, Minia University, El-Minia, Egypt.
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University
3Pharmacology and Toxicology Department, Faculty of Pharmacy, South Valley University, South Valley, Egypt.
Abstract
Pulmonary hypertension (PH) is a life threatening pulmonary vascular disease, characterized by elevated pulmonary arterial pressure (PAP), pulmonary vascular remodeling and right sided heart hypertrophy. Due to the emergence of right ventricular (RV) failure, PH, in spite of recent therapeutic improvements, continues to be a fatal condition. Although there are already many animal models of pulmonary hypertension accessible in research, improvement in RV function and effective remodeling reversal remain a therapeutic challenge. The right utilization of traditional and novel PH animal models is crucial for understanding the underlying pathological mechanisms to reverse severe phenomenon. This review gives a general summary of the various models for PH induction, along with each method's benefits and drawbacks.
Keywords
Animal models; Chronic hypoxia; Monocrotaline; Sugen; Pulmonary hypertension
Main Subjects
Pharmacology and Toxicology
Statistics
Article View: 246
PDF Download: 561
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.